These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

795 related articles for article (PubMed ID: 33278625)

  • 1. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness.
    Ahmed S; Karim MM; Ross AG; Hossain MS; Clemens JD; Sumiya MK; Phru CS; Rahman M; Zaman K; Somani J; Yasmin R; Hasnat MA; Kabir A; Aziz AB; Khan WA
    Int J Infect Dis; 2021 Feb; 103():214-216. PubMed ID: 33278625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ivermectin for preventing and treating COVID-19.
    Popp M; Stegemann M; Metzendorf MI; Gould S; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD015017. PubMed ID: 34318930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.
    Vallejos J; Zoni R; Bangher M; Villamandos S; Bobadilla A; Plano F; Campias C; Chaparro Campias E; Achinelli F; Guglielmone HA; Ojeda J; Medina F; Farizano Salazar D; Andino G; Ruiz Diaz NE; Kawerin P; Meza E; Dellamea S; Aquino A; Flores V; Martemucci CN; Vernengo MM; Martinez SM; Segovia JE; Aguirre MG
    Trials; 2020 Nov; 21(1):965. PubMed ID: 33234158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial.
    Garcia PJ; Mundaca H; Ugarte-Gil C; Leon P; Malaga G; Chaccour C; Carcamo CP
    Trials; 2021 Apr; 22(1):262. PubMed ID: 33836826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
    Naggie S; Boulware DR; Lindsell CJ; Stewart TG; Gentile N; Collins S; McCarthy MW; Jayaweera D; Castro M; Sulkowski M; McTigue K; Thicklin F; Felker GM; Ginde AA; Bramante CT; Slandzicki AJ; Gabriel A; Shah NS; Lenert LA; Dunsmore SE; Adam SJ; DeLong A; Hanna G; Remaly A; Wilder R; Wilson S; Shenkman E; Hernandez AF;
    JAMA; 2022 Oct; 328(16):1595-1603. PubMed ID: 36269852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Hosseini FS; Malektojari A; Ghazizadeh S; Hassaniazad M; Davoodian P; Dadvand H; Nikpoor AR; Nikoofal-Sahlabadi S; Kahoori S; Sepandi M; Hassanipour S; Fathalipour M
    Trials; 2021 Jan; 22(1):4. PubMed ID: 33397429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial.
    López-Medina E; López P; Hurtado IC; Dávalos DM; Ramirez O; Martínez E; Díazgranados JA; Oñate JM; Chavarriaga H; Herrera S; Parra B; Libreros G; Jaramillo R; Avendaño AC; Toro DF; Torres M; Lesmes MC; Rios CA; Caicedo I
    JAMA; 2021 Apr; 325(14):1426-1435. PubMed ID: 33662102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial.
    Vallejos J; Zoni R; Bangher M; Villamandos S; Bobadilla A; Plano F; Campias C; Chaparro Campias E; Medina MF; Achinelli F; Guglielmone HA; Ojeda J; Farizano Salazar D; Andino G; Kawerin P; Dellamea S; Aquino AC; Flores V; Martemucci CN; Martinez SM; Segovia JE; Reynoso PI; Sosa NC; Robledo ME; Guarrochena JM; Vernengo MM; Ruiz Diaz N; Meza E; Aguirre MG
    BMC Infect Dis; 2021 Jul; 21(1):635. PubMed ID: 34215210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-COVID property of subcutaneous ivermectin in synergy with zinc among midlife moderately symptomatic patients: a structured summary of a study protocol for a randomised controlled trial.
    Ashraf S; Ashraf S; Farooq I; Ashraf S; Ashraf M; Imran MA; Kalsoom L; Akmal R; Ghufran M; Rafique S; Akram MK; Habib Z; Siddiqui UN; Ahmad A; Arshad S; Virk MAR; Gul M; Awais AB; Hassan M; Sherazi SSH; Safdar Z; Munir I; Khalid H; Munir K; Majeed N; Alahmadi YM; Humayun A; Saboor QA; Ahmad A; Ashraf M; Izhar M;
    Trials; 2021 Sep; 22(1):591. PubMed ID: 34488858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of single-dose and double-dose ivermectin early treatment in preventing progression to hospitalization in mild COVID-19: A multi-arm, parallel-group randomized, double-blind, placebo-controlled trial.
    Mirahmadizadeh A; Semati A; Heiran A; Ebrahimi M; Hemmati A; Karimi M; Basir S; Zare M; Charlys da Costa A; Zeinali M; Sargolzaee M; Eilami O
    Respirology; 2022 Sep; 27(9):758-766. PubMed ID: 35738778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial.
    Buonfrate D; Chesini F; Martini D; Roncaglioni MC; Ojeda Fernandez ML; Alvisi MF; De Simone I; Rulli E; Nobili A; Casalini G; Antinori S; Gobbi M; Campoli C; Deiana M; Pomari E; Lunardi G; Tessari R; Bisoffi Z
    Int J Antimicrob Agents; 2022 Feb; 59(2):106516. PubMed ID: 34999239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Ivermectin as a Potential Treatment for Mild to Moderate COVID-19: A Double-Blind Randomized Placebo Controlled Trial in Eastern India.
    Ravikirti ; Roy R; Pattadar C; Raj R; Agarwal N; Biswas B; Manjhi PK; Rai DK; Shyama ; Kumar A; Sarfaraz A
    J Pharm Pharm Sci; 2021; 24():343-350. PubMed ID: 34265236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Early Treatment with Ivermectin among Patients with Covid-19.
    Reis G; Silva EASM; Silva DCM; Thabane L; Milagres AC; Ferreira TS; Dos Santos CVQ; Campos VHS; Nogueira AMR; de Almeida APFG; Callegari ED; Neto ADF; Savassi LCM; Simplicio MIC; Ribeiro LB; Oliveira R; Harari O; Forrest JI; Ruton H; Sprague S; McKay P; Guo CM; Rowland-Yeo K; Guyatt GH; Boulware DR; Rayner CR; Mills EJ;
    N Engl J Med; 2022 May; 386(18):1721-1731. PubMed ID: 35353979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial.
    Manomaipiboon A; Pholtawornkulchai K; Poopipatpab S; Suraamornkul S; Maneerit J; Ruksakul W; Phumisantiphong U; Trakarnvanich T
    Trials; 2022 Aug; 23(1):714. PubMed ID: 36028897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial.
    Mohan A; Tiwari P; Suri TM; Mittal S; Patel A; Jain A; Velpandian T; Das US; Boppana TK; Pandey RM; Shelke SS; Singh AR; Bhatnagar S; Masih S; Mahajan S; Dwivedi T; Sahoo B; Pandit A; Bhopale S; Vig S; Gupta R; Madan K; Hadda V; Gupta N; Garg R; Meena VP; Guleria R
    J Infect Chemother; 2021 Dec; 27(12):1743-1749. PubMed ID: 34483029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ivermectin compared with placebo in the clinical course in Mexican patients with asymptomatic and mild COVID-19: a randomized clinical trial.
    de la Rocha C; Cid-López MA; Venegas-López BI; Gómez-Méndez SC; Sánchez-Ortiz A; Pérez-Ríos AM; Llamas-Velázquez RA; Meza-Acuña AI; Vargas-Íñiguez B; Rosales-Galván D; Tavares-Váldez A; Luna-Gudiño N; Hernández-Puente CV; Milenkovic J; Iglesias-Palomares C; Méndez-Del Villar M; Gutiérrez-Dieck GA; Valderrábano-Roldán CG; Mercado-Cerda J; Robles-Bojórquez JG; Mercado-Sesma AR
    BMC Infect Dis; 2022 Dec; 22(1):917. PubMed ID: 36482326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical, Biochemical and Molecular Evaluations of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Reducing Upper Respiratory Symptoms of Mild COVID-19.
    Aref ZF; Bazeed SEES; Hassan MH; Hassan AS; Rashad A; Hassan RG; Abdelmaksoud AA
    Int J Nanomedicine; 2021; 16():4063-4072. PubMed ID: 34163159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.